Observation of the efficacy of Eureklin in the treatment of progressive cerebral infarction in young and middle-aged people outside the thrombolytic time window
10.3760/cma.j.issn.1008-6706.2020.04.002
- VernacularTitle:尤瑞克林治疗溶栓时间窗外中青年人进展性脑梗死的疗效观察
- Author:
Mingzhan WU
1
;
Liguo ZHANG
Author Information
1. 广东省
- Keywords:
Infarction,middle cerebral artery;
Thrombolytic therapy;
Stroke;
Activities of daily living;
Middle aged;
Eureklin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(4):389-393
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of Eureklin in the treatment of progressive cerebral infarction in young and middle-aged people outside the thrombolytic time window (the onset time was more than 6h).Methods From March 2016 to March 2019,120 young and middle-aged patients with progressive brain infarction who admitted to the neurology department of Chaonan Minsheng Hospital were selected and all patients were confirmed by cranial CT or MRI.They were divided into two groups by random drawing method.Clinical conventional therapy was applied in the control group (60 cases),and on the basis of conventional treatment,Eureklin intravenous drips was used in the treatment group (60 cases).Before and after treatment 14d,the national institutes of health stroke scale(NIHSS),daily living ability scale(ADL) were used to assessment of neurological impairment and Barthel index in patients.At the same time,the drug side effects and adverse reactions were observed.Results After treatment,the NIHSS score in the conventional treatment group[(3.4 ± 0.3)points] was lower than that in the Eureklin group[(4.1 ± 0.4) points],and the ADLscore in the conventional treatment group [(67.5 ± 24.8) points] was higher than that in the Eureklin group[(57.8± 26.7) points],the difference was statistically significant(t =0.014,0.003,all P ＜ 0.05).The total effective rate of the treatment group [83.33％ (50/60)] was higher than that of the control group [71.67％ (43/60)],the difference was statistically significant (x2 =3.596,P ＜ 0.05).At the same time,no serious adverse reactions were found in the Eureklin treatment group.Conclusion For young and middle-aged patients with progressive cerebral infarction outside the thrombolytic time window,the application of Eureklin can improve the patients' symptoms of neurological dysfunction,improve the ability of daily life,and without serious adverse events such as bleeding,which is worthy of clinical application.
